SCHEMBL3105173

SCHEMBL3105173

COC(=O)c1ccc(OC(c2cc(-c3ccncc3)oc2C)C2CCCCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
HPGD P15428 2/20 0.38
RAB9A P51151 1/20 0.38
ADCY1 Q08828 1/20 0.36
THRB P10828 1/20 0.36
ALDH1A1 P00352 2/20 0.36
EPHX2 P34913 1/20 0.36
GSK3B P49841 2/20 0.35
GSK3A P49840 1/20 0.35
MMP13 P45452 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPT P10636 1/20 0.35
EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095590 0.90 MMP13 (0.44) SMN1; SMN2NPC1HPGDRAB9AALDH1A1
SCHEMBL3096197 0.90 SMN1; SMN2 (0.37) SMN1; SMN2NPC1HPGDRAB9AADCY1
SCHEMBL3109825 0.89 SLC2A1 (0.43) SMN1; SMN2NPC1HPGDRAB9AALDH1A1
SCHEMBL3095547 0.87 ALDH1A1 (0.45) SMN1; SMN2HPGDRAB9AALDH1A1MEN1
SCHEMBL3098670 0.84 KDM4E (0.39) SMN1; SMN2NPC1HPGDRAB9AMMP13
SCHEMBL3102215 0.84 GCGR (0.48) SMN1; SMN2NPC1HPGDRAB9AADCY1
SCHEMBL3107066 0.84 SMN1; SMN2 (0.44) SMN1; SMN2NPC1HPGDRAB9AADCY1
SCHEMBL3099764 0.84 ROCK2 (0.35) SMN1; SMN2NPC1HPGDRAB9AADCY1
SCHEMBL3106857 0.82 ALDH1A1 (0.44) SMN1; SMN2HPGDRAB9AALDH1A1MEN1
SCHEMBL3106997 0.82 ALDH1A1 (0.43) SMN1; SMN2NPC1HPGDRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR SMN1; SMN2 4692/4885NPC1 3994/4885HPGD 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.